Gene Target's Global Launch of the Precision Health Ecosystem

Taiwan’s Biomedical Leader Gene Target Group Commercializes Key Patented Technologies for Global Expansion

Gene Target Group, a pioneer in Taiwan’s biomedical sector, has successfully commercialized multiple core patented technologies and is now expanding its innovative solutions to the global market.

Dr. Yi-Fang Chen, founder of Gene Target Group, emphasized that the company has spent years cultivating expertise in precision health technologies. Through continuous innovation in health services and product development, Gene Target has established two major business pillars: Precision Health Intelligence and Genetic Engineering. These have yielded impressive outcomes, including partnerships with over 10,000 global retail outlets and 100+ alliance brands, laying the foundation for the world’s first Precision Health Ecosystem — making advanced health products and services accessible, efficient, and impactful for everyone. The company aims to serve over 5 million people worldwide within the next three years, unlocking a multi-billion-dollar market opportunity.

AI + Big Data: Industry-First Real-Time Health Management System

Recognizing that both genetic (innate) and environmental (acquired) factors impact health, Gene Target Group has developed a groundbreaking AI-driven real-time health monitoring system, using millions of data points. This patented invention offers immediate analysis of key health indicators via wearable devices and a mobile app, solving the long-standing challenge of delayed or inaccessible health insights.

Intelligent Health Database: Personalized Wellness Solutions

Another major invention integrates professional medical databases — including nutrition, sports science, preventive medicine, and clinical health — with AI to provide real-time lifestyle guidance and customized health advice. When medical intervention is needed, users are instantly referred to certified medical providers. The platform also offers over 1,000 carefully selected health and wellness products, developed under rigorous patent-based quality assurance.

Breakthroughs in Gene Banking & Cellular Engineering: Leading Regenerative Medicine

Gene Target has built extensive genomic databases — covering cancer, chronic disease, infectious pathogens, and pediatric health — to form a comprehensive Gene Bank. The company has patented a fully automated nucleic acid analysis system, capable of rapid viral detection, including emerging threats like COVID-19, dramatically reducing testing time and risk to lab personnel. Integrated with their AI health platform, Gene Target is also developing disease prediction and prevention systems.

In the realm of stem cell innovation, the company has developed an automated cell selection and identification system, supporting cell line verification, activity analysis, and differentiation assessment. These breakthroughs bolster the efficiency and efficacy of stem cell applications in regenerative therapies. Currently, the company is expanding R&D into liver and kidney cell differentiation, aiming to address the global demand for treating chronic liver cirrhosis and kidney failure — potentially benefiting millions of patients.

Expanding into Pet Health: Capturing the Booming “Pet Economy”

With over NT$50 billion (USD $1.5 billion) in market value, Taiwan’s pet industry is thriving. Gene Target Group, leveraging two decades of human health experience, has extended its patented technology to create the world’s first Pet Precision Health Ecosystem.

This includes:

• Pet gene and cell data centers

• AI-powered precision pet health platforms

• Genetic testing, stem cell storage and therapy

• Tailored nutrition and wellness products

By combining veterinary science, AI, and big data, the platform delivers personalized pet health management — from diagnostics and lifestyle tracking to ongoing wellness care. Through diet, regular checkups, and tailored supplements, the system aims to optimize pets’ health and well-being, placing Gene Target in a leading global position in the pet health market.